Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A target for tumour-directed therapy

Nature Medicine volume 1, pages 631–632 (1995)Cite this article

Specific antibodies can slow tumour progression, setting the stage for tumour-cell elimination (pages 644–648).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A. & Greene, M.I. Down-modulation of an oncogene protein product and reversion of the transformed phe-notype by monoclonal antibodies. Cell 41, 695–706 (1985).

    Article  Google Scholar 

  2. Drebin, J.A., Link, V.C., Weinberg, R.A. & Greene, M.I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. natn. Acad. Sci. USA. 83, 9129–9133 (1986).

    Article  CAS  Google Scholar 

  3. Katsumata, M. et al. Prevention of breast tumor development in vivo by downregulation of the p185neu receptor. Nature Med. 1, 644–648 (1995).

    Article  CAS  Google Scholar 

  4. Bouchard, L., Lamarre, L., Tremblay, P.J. & Jolicoeur, P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57, 931–936 (1989).

    Article  CAS  Google Scholar 

  5. Stöcklin, E., Botteri, F. & Groner, B. An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J. cell Biol. 122, 199–208 (1993).

    Article  Google Scholar 

  6. Deshane, J. et al. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther. 1, 332–337 (1994).

    CAS  PubMed  Google Scholar 

  7. Bacus, S.S. et al. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res. 52, 2580–2589 (1992).

    CAS  PubMed  Google Scholar 

  8. Marte, B.M. et al. NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. Oncogene 10, 167–175 (1995).

    CAS  PubMed  Google Scholar 

  9. Masui, H. et al. Growth inhibition of human tumor cells in athymic nude mice by anti-epidermal-growth-factor-receptor monoclonal antibodies. Cancer Res. 44, 1002–1007 (1984).

    CAS  PubMed  Google Scholar 

  10. Divgi, C.R. et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. natn. Cancer Inst. 83, 97–104 (1991).

    Article  CAS  Google Scholar 

  11. Hudziak, R.M., Lewis, G.D., Winget, M., Fendly, B.M., Shepard, H.M. & Ullrich, A. pl85HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Molec. cell. Biol. 9, 1165–1172 (1989).

    Article  CAS  Google Scholar 

  12. Harwerth, I.-M., Wels, W., Schlegel, J., Muller, M. & Hynes, N.E. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 68, 1140–1145 (1993).

    Article  CAS  Google Scholar 

  13. Pietras, R.J., Fendly, B.M., Chazin, V.R., Pegram, M.D., Howell, S.B. & Slamon, D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9, 1829–1838 (1994).

    CAS  PubMed  Google Scholar 

  14. Arteaga, C.L. et al. p185c-erbB-2 signaling enhances cis-platin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogeneic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res. 54, 3758–3765 (1994).

    CAS  PubMed  Google Scholar 

  15. Beerli, R.R., Wels, W. & Hynes, N.E. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J. biol. Chem. 39, 23931–23936 (1994).

    Google Scholar 

  16. Wels, W. et al. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human ErbB-2 receptor. Biotechnology 10, 1128–1132 (1992).

    CAS  PubMed  Google Scholar 

  17. Wels, W., Harwerth, I.M., Mueller, M., Groner, B. & Hynes, N.E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 52, 6310–6317 (1992).

    CAS  PubMed  Google Scholar 

  18. Batra, J.K., Kasprzyk, P.G., Bird, R.E., Pastan, I. & King, C.R. Recombinant anti-erbB-2 immunotoxins containing Pseudomonas exotoxin. Proc. natn. Acad. Sci. USA. 89, 5867–5871 (1992).

    Article  CAS  Google Scholar 

  19. Jeschke, M. et al. Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins. Int. J. Cancer 60, 730–739 (1995).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich Miescher Institute, CH-4002, Basel, Switzerland

    Nancy E. Hynes

  2. Institute for Experimental Cancer Research, D-79106, Freiburg, Germany

    Bernd Groner

Authors
  1. Nancy E. Hynes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernd Groner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hynes, N., Groner, B. A target for tumour-directed therapy. Nat Med 1, 631–632 (1995). https://doi.org/10.1038/nm0795-631

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0795-631

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing